Have your say!
Would you like to share your views to help improve programs and services for patients, or help researchers gain a better understanding of the challenges of living with kidney disease?
Our Kidney Community Contact List is a national and confidential record of people willing to be contacted for their feedback and action on topics of concern to people living with kidney disease. Join our contact list and we will contact you as opportunities arise.
Walking and Health in Adults with a Kidney Transplant
Researchers at Athabasca University want to learn about the health outcomes associated with walking behaviour in adult kidney transplant recipients.
Study participants must be over the age of 18, have a functioning kidney transplant, be able to walk without assistance (cane, walker, wheelchair), and be able to read and understand English. Participants will be asked to wear a pedometer for three days and record their number of steps, then complete and return a survey (postage paid).
Download this document for more information or contact Ms. Josée Raymond at 249-878-0088 or via email at firstname.lastname@example.org.
Clinical Trial Studying New Non-surgical Vascular Access Method for Hemodialysis
The Novel Endovascular Access Trial (NEAT) is evaluating the safety and efficacy of the FLEX endoAVF System from TVA Medical, a device that creates an arteriovenous fistula (AVF) in a percutaneous procedure, without general anesthesia or surgery. In the procedure, two thin, flexible magnetic catheters are inserted in an artery and vein in the arm. A small burst of radiofrequency energy is used to connect the artery and vein to create the fistula, and the catheters are removed. The procedure is designed to enable patients to use their AVF for hemodialysis within one to two months.
Five hospitals in Canada are enrolling up to 70 patients in total who will be followed for 12 months in the NEAT clinical trial. The centers include St. Paul’s Hospital in Vancouver; Montreal University Health Centre (CHUM) in Montreal; Toronto General Hospital in Toronto; Lakeridge Health in Oshawa, Ontario; and Victoria Hospital in London, Ontario. NEAT study participants must be willing to travel to one of the trial sites on a monthly basis for one year for hemodialysis and follow-up appointments.
Patients with end-stage (stage IV or V) renal disease interested to enroll in this trial should read this Patient FAQ and talk to their nephrologist before contacting the participating hospital in their region.